Want to see EXOZ full AI Analyst Report?
Top Page
eXoZymes
(NASDAQ:EXOZ)
Select Model
Select Model
Rating:43Neutral
Price Target:
$4.50
▲(2.27% Upside)
Action:Reiterated
Date:07/21/26
The score is primarily weighed down by weak financial performance (pre-revenue, widening losses, and significant cash burn with a shrinking equity base) and bearish technicals (trading well below key moving averages with negative MACD). Corporate events provide some offset via non-dilutive NIH funding, but repeated financing activity and warrant structures elevate dilution risk, and valuation signals remain constrained by ongoing losses.
Positive Factors
Non-dilutive NIH funding
The $2.03M NIH Phase IIB award provides two-year non-dilutive funding targeted at cannabinoid enzyme development and preclinical assays. This reduces near-term financing pressure, directly funds R&D milestones, and strengthens the company’s ability to advance candidates and attract partners without immediate equity dilution.
Negative Factors
Pre-revenue, widening losses
The company remains pre-commercial with escalating operating losses and persistently negative operating and free cash flow. Without near-term revenue, continuing burn increases reliance on external financing and elevates execution risk: sustained losses can delay development timelines and pressure resources over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Non-dilutive NIH funding
The $2.03M NIH Phase IIB award provides two-year non-dilutive funding targeted at cannabinoid enzyme development and preclinical assays. This reduces near-term financing pressure, directly funds R&D milestones, and strengthens the company’s ability to advance candidates and attract partners without immediate equity dilution.
Read all positive factors
eXoZymes (EXOZ) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$42.69M
Dividend YieldN/A
Average Volume (3M)2.40K
Price to Earnings (P/E)―
Beta (1Y)1.32
Revenue GrowthN/A
EPS Growth-32.48%
CountryUS
Employees32
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.15
Shares Outstanding9,281,359
10 Day Avg. Volume1,191
30 Day Avg. Volume2,398
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)26.89
Price to Sales (P/S)0.00
P/FCF Ratio-13.69
Enterprise Value/Market Cap1.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-14.65K
Enterprise Value/Ebitda-5.42
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
eXoZymes Business Overview & Revenue Model
Company Description
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, ...
How the Company Makes Money
null...
eXoZymes Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -267.38K | 0.00 | -147.75K | -59.41K |
| EBITDA | -8.98M | -5.59M | -1.80M | -1.18M | -1.15M |
| Net Income | -9.16M | -5.86M | -2.04M | -1.40M | -1.21M |
Balance Sheet | |||||
| Total Assets | 5.97M | 13.03M | 3.56M | 2.69M | 2.35M |
| Cash, Cash Equivalents and Short-Term Investments | 3.04M | 9.72M | 66.53K | 558.57K | 547.81K |
| Total Debt | 1.24M | 1.39M | 1.61M | 608.77K | 720.63K |
| Total Liabilities | 2.57M | 2.61M | 3.94M | 1.31M | 1.15M |
| Stockholders Equity | 3.40M | 10.42M | -384.32K | 1.37M | 1.20M |
Cash Flow | |||||
| Free Cash Flow | -6.67M | -8.90M | -1.47M | -1.44M | -2.01M |
| Operating Cash Flow | -6.50M | -8.51M | -1.18M | -1.26M | -1.59M |
| Investing Cash Flow | -150.22K | -359.22K | -311.17K | -87.21K | -312.25K |
| Financing Cash Flow | -27.71K | 18.52M | 1.00M | 1.36M | 2.31M |
eXoZymes Risk Analysis
eXoZymes disclosed 46 risk factors in its most recent earnings report. eXoZymes reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
Changes to United States tariff and import/export regulations may have an adverse effect on our business, financial condition and results of operations. Q1, 2026
2.
Government Action on tariffs and research grants and other funding may impede our ability to conduct our research and to raise capital by and for our partner companies and other clients. Q1, 2026
eXoZymes Peers Comparison
UnderperformOutperform
Sector (55)
EXOZ
eXoZymes
4.65
-5.29
-53.22%
BDRX
Biodexa Pharmaceuticals
1.32
-33.58
-96.22%
ADTX
Aditxt
0.04
-24,102.86
-100.00%
NCEL
NewcelX
3.49
-15.38
-81.50%
VRAX
Virax Biolabs Group Ltd. Class A
2.62
-18.13
-87.37%
eXoZymes Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
eXoZymes Completes New Securities Offering to Fund Pipeline
Positive
Jul 1, 2026
On June 30, 2026, eXoZymes Inc. closed a registered securities offering of 35,555 units, each comprising one common share and one warrant, at $18.00 per unit, raising gross proceeds of about $640,000 and net proceeds after fees and expenses of rou...
Business Operations and StrategyPrivate Placements and Financing
eXoZymes Secures NIH Grant to Advance Cannabinoid Pipeline
Positive
Jun 26, 2026
On June 24, 2026, eXoZymes Inc. announced it had secured a $2.03 million Phase IIB Small Business Innovation Research grant from the National Institute of General Medical Sciences of the NIH to advance rare cannabinoid production and engineered ca...
Business Operations and StrategyPrivate Placements and Financing
eXoZymes Completes Nasdaq Equity Offering to Fund Pipeline
Positive
Jun 17, 2026
On June 17, 2026, Los Angeles-based eXoZymes Inc. announced the closing of an underwritten public offering of 330,575 units of common stock and warrants on Nasdaq, including 34,440 units issued through a partial exercise of the underwriters’...
Business Operations and StrategyPrivate Placements and Financing
eXoZymes Announces Public Equity Offering to Fund Growth
Positive
Jun 8, 2026
On June 5, 2026, eXoZymes Inc. entered into an underwriting agreement with MDB Capital for a firm commitment public offering of 592,270 common shares and 292,135 warrants, sold as units of two shares and one warrant at $18.00 per unit. The transac...
Business Operations and StrategyPrivate Placements and Financing
eXoZymes Prepares Investor Presentation for Proposed Public Offering
Positive
May 7, 2026
On May 7, 2026, eXoZymes Inc., a Nevada corporation, circulated an investor presentation to potential underwriters, offering participants, and prospective investors. The materials were prepared in connection with a proposed public offering of the ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.